CAMBRIDGE, Mass. & MADRID–(BUSINESS WIRE)–Nov. 16, 2011— Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Sylentis, S.A., a Spanish bio-pharmaceutical company devoted to the research and development of new therapies based on RNAi, announced today that Alnylam has granted Sylentis a non-exclusive option for a new target-specific InterfeRx™ license. This license would […]
Author Archives: Manuel Simbionte
SYL1001 is a new compound arising from Sylentis’s research in ophthalmological disorders It is indicated for treating eye discomfort associated with dry eye syndrome SYL1001 is a form of interference RNA (RNAi) SYL1001 inhibits the capsaicin receptor TrpV1, which is expressed on the surface of the eye Madrid, 6 June 2011: Sylentis, […]
Sylentis, a biopharmaceutical company in Grupo Zeltia (MC:ZEL) which is a pioneer in the research and development of new drugs based on gene silencing (interference RNA: RNAi) and one of the four companies in the world with RNAi-based products undergoing clinical trials, has been authorised as a pharmaceutical laboratory to manufacture research drugs by the […]
SYL040012 is a new compound developed in Sylentis’s R&D programme in ophthalmological disorders such as ocular hypertension and glaucoma. SYL040012 is a form of RNA interference (RNAi). It reduces intraocular pressure by inhibiting the expression of ß-adrenergic receptors. Madrid, 22 November 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and a pioneer in the […]
SYL040012 is a new compound arising from Sylentis’s research in ophthalmological disorders. It is indicated for treating ocular hypertension and preventing glaucoma. SYL040012 is a form of interference RNA (RNAi). It reduces intraocular pressure by inhibiting the expression of β-adrenergic receptors. Madrid, 6 September 2010: Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia (MC: ZEL) and […]
Find this publication at: Sylentis reviews present knowledge on RNA interference applications Lopez-Fraga, M. et al. Biodrugs. 2009; 23(5):305-32.
Español